This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Valuation

Is MOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOR?

Key metric: As MOR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MOR. This is calculated by dividing MOR's market cap by their current revenue.
What is MOR's PS Ratio?
PS Ratio	10.5x
Sales	€241.47m
Market Cap	€2.53b

MOR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	17.1x
Enterprise Value/EBITDA	-9.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MOR's PS Ratio compare to its peers?

The above table shows the PS ratio for MOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.1x
ACAD ACADIA Pharmaceuticals	2.9x	9.1%	US$2.7b
FOLD Amicus Therapeutics	5.8x	19.5%	US$2.9b
PTCT PTC Therapeutics	3.7x	5.5%	US$3.3b
TWST Twist Bioscience	8x	14.7%	US$2.5b
MOR MorphoSys	10.5x	25.0%	US$2.5b

Price-To-Sales vs Peers: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the peer average (5.6x).

Price to Sales Ratio vs Industry

How does MOR's PS Ratio compare vs other companies in the US Biotechs Industry?

129 Companies	Price / Sales	Estimated Growth	Market Cap
GILD Gilead Sciences	4x	2.4%	US$112.40b
BIIB Biogen	2.4x	1.3%	US$23.01b
MRNA Moderna	3.1x	6.8%	US$15.82b
INCY Incyte	3.4x	8.9%	US$13.82b

129 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: MOR is good value based on its Price-To-Sales Ratio (10.5x) compared to the US Biotechs industry average (11.7x).

Price to Sales Ratio vs Fair Ratio

What is MOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	10.5x
Fair PS Ratio	9.2x

Price-To-Sales vs Fair Ratio: MOR is expensive based on its Price-To-Sales Ratio (10.5x) compared to the estimated Fair Price-To-Sales Ratio (9.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

4.7%

-4.8%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

1.3%

15.1%